Dorzagliatin

DRUG12 trials

Sponsors

Hua Medicine Limited, Chinese University of Hong Kong, University of Alabama at Birmingham, Yan Bi, Elaine Chow

Conditions

Chronic Kidney Disease (Stages 3b-5)Chronic Renal InsufficiencyCystic Fibrosis-related DiabetesDiabetes MellitusDiabetes Mellitus, Type 2Diabetic Nephropathy Type 2Drug InteractionGlucose Homeostasis

Phase 1

Drug Interaction Study Between Dorzagliatin and Empagliflozin

CompletedNCT03790787

Hua Medicine LimitedPatients

Start: 2019-04-18End: 2020-03-15Updated: 2025-03-24

Drug Interaction Study Between Dorzagliatin and Sitagliptin

CompletedNCT03790839

Hua Medicine LimitedPatients

Start: 2019-01-31End: 2019-08-30Updated: 2023-02-28

DDI Study Between Dorzagliatin and Rifampicin

CompletedNCT04080609

Hua Medicine LimitedDrug Interaction

Start: 2018-03-27End: 2018-04-17Updated: 2019-09-06

DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin

CompletedNCT04080596

Hua Medicine LimitedDrug Interaction

Start: 2017-10-13End: 2017-12-05Updated: 2019-09-06

Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT

Chinese University of Hong KongGlucose Intolerance

Start: 2022-08-31End: 2023-04-30Target: 20Updated: 2022-07-25

Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis

RecruitingNCT06995651

Michael R. Rickels, MD, MSCystic Fibrosis-related Diabetes, Pancreatic Insufficiency

Start: 2025-10-21End: 2027-07-01Target: 15Updated: 2026-08-31

Phase 2

Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes

CompletedNCT04531631

Chinese University of Hong KongDiabetes Mellitus, Type 2

Start: 2020-09-30End: 2022-02-15Updated: 2022-07-22

Glucokinase Activator in Monogenic Diabetes

RecruitingNCT06976658

Chinese University of Hong KongDiabetes Mellitus, Monogenic Diabetes

Start: 2025-04-30End: 2026-12-31Target: 44Updated: 2026-04-30

Phase 3

Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

Active, not recruitingNCT05098470

University of Alabama at BirminghamType 2 Diabetes

Start: 2022-03-07End: 2026-07-29Target: 100Updated: 2025-07-30

Unknown Phase

Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.

Not yet recruitingNCT06222476

Yan BiDiabetic Nephropathy Type 2

Start: 2024-02-20End: 2026-06-30Target: 106Updated: 2024-01-24

Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

Not yet recruitingNCT06671340

Elaine ChowDiabetes Mellitus, Prediabetes / Type 2 Diabetes

Start: 2025-04-02End: 2026-01-31Target: 30Updated: 2025-03-04

Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

Not yet recruitingNCT07786571

Sun Yat-sen UniversityChronic Kidney Disease (Stages 3b-5), Chronic Renal Insufficiency, Glucose Homeostasis +1

Start: 2026-12-01End: 2029-07-01Target: 206Updated: 2026-08-26

Related Papers

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.

2026-04-21

A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity

2025-02-18

A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity.

2023-03-149 citations

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.

2022-05-1253 citations